Access cutting-edge lung cancer treatment through this clinical trial at a research site in Palo Alto. Study-provided care at no cost to qualified participants.
Access lung cancer specialists in Palo Alto at no cost
This study follows strict safety protocols and ethical guidelines
All study-related lung cancer treatment provided free
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.
Sponsor: Eli Lilly and Company
Check if you qualify for this lung cancer clinical trial in Palo Alto, CA
If you're searching for lung cancer treatment options in Palo Alto, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Palo Alto research site is actively enrolling participants for this clinical trial. You'll receive care from experienced lung cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.